Ionis falls after AstraZeneca-partnered drug fails late-stage heart disease trial
09/07/2026 10:29
BUZZ-Ionis falls after AstraZeneca-partnered drug fails late-stage heart disease trial ** Ionis Pharmaceuticals IONS.O slides 21.8% premarket to $67.80
** Co's nerve disease drug Wainua, made in partnership with AstraZeneca AZN.L fails to meet main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial
** Setback dents what analysts predicted could be a $2 billion peak-sales opportunity for the drug
** Shares of Alnylam Pharmaceuticals ALNY.O and BridgeBio Pharma BBIO.O which have approved drugs for the disease, are up 15.3% and 9.9% respectively
** As of last close, IONS up 6.7% YTD
(Reporting by Sudeshna Ghoshal in Bengaluru)
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study